Title : Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.

Pub. Date : 2016 Jul

PMID : 27121230






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The present study aimed to elucidate the anticancer effects of PI3K (BKM120) and MEK (PD1056309) inhibitors on NSCLC cell lines with KRAS or EGFR mutations. NVP-BKM120 epidermal growth factor receptor Homo sapiens
2 Inhibition of the EGFR and KRAS downstream P13K pathway using BKM120 significantly inhibited the growth of NSCLC cell lines with either EGFR or KRAS mutations. NVP-BKM120 epidermal growth factor receptor Homo sapiens
3 Inhibition of the EGFR and KRAS downstream P13K pathway using BKM120 significantly inhibited the growth of NSCLC cell lines with either EGFR or KRAS mutations. NVP-BKM120 epidermal growth factor receptor Homo sapiens